기관지폐이형성증 시장 규모, 점유율, 성장 분석 : 치료법별, 약물 계열별, 최종사용자별, 환자 그룹별, 유통 채널별, 질환 중증도별, 지역별 - 업계 예측(2026-2033년)

Global Bronchopulmonary Dysplasia Market size was valued at USD 842.6 Million in 2024 and is poised to grow from USD 908.32 Million in 2025 to USD 1656.5 Million by 2033, growing at a CAGR of 7.8% during the forecast period (2026-2033).

The market for Global Bronchopulmonary Dysplasia is significantly influenced by the rise of precision medicine platforms that integrate genetic profiling with pulmonary monitoring, enabling customized therapeutic approaches and minimizing ventilation durations. This trend fosters the need for wearable biosensors, cloud-based analytics, and companion diagnostics, prompting increased venture capital investments and expedited product development. Notably, a pioneering chest-wall sensor has demonstrated a substantial decrease in oxygen dependency in infants upon receiving personalized surfactant dosing during trials. Such advancements not only lead to cost reductions for neonatal care but also enhance long-term health outcomes, thus facilitating broader adoption and paving the way for reimbursement opportunities, which collectively contribute to an expanding market landscape in affluent regions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Bronchopulmonary Dysplasia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Bronchopulmonary Dysplasia Market Segments Analysis

Global bronchopulmonary dysplasia market is segmented by treatment type, drug class, end user, patient group, distribution channel, disease severity and region. Based on treatment type, the market is segmented into Pharmacological Treatment, Respiratory Support, Nutritional Therapy and Others. Based on drug class, the market is segmented into Corticosteroids, Bronchodilators, Diuretics and Others. Based on end user, the market is segmented into Neonatal Intensive Care Units, Hospitals, Specialty Clinics and Others. Based on patient group, the market is segmented into Preterm Infants and Full-Term Infants. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Others. Based on disease severity, the market is segmented into Mild, Moderate and Severe. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Bronchopulmonary Dysplasia Market

The increasing prevalence of premature births is a significant catalyst for the Global Bronchopulmonary Dysplasia market, as neonates are at a heightened risk for lung injuries. This vulnerability compels healthcare providers to seek advanced respiratory support solutions to reduce the potential for chronic complications. As a result, hospitals are inclined to implement newer therapies and monitoring technologies. This intensified focus in clinical settings not only boosts procurement volumes but also encourages further investments in research and development, leading to a strong pipeline of innovative products. Ultimately, this environment fosters rapid market growth, broadening patient access and enhancing awareness of long-term health and quality-of-life improvements for survivors worldwide.

Restraints in the Global Bronchopulmonary Dysplasia Market

The high costs linked to advanced treatments for bronchopulmonary dysplasia create a substantial obstacle for numerous healthcare providers, especially in environments with limited resources. Reimbursement policies frequently do not keep pace with technological innovations, leading to insufficient coverage and increased out-of-pocket expenses for patients. As a result, healthcare facilities may postpone the integration of expensive new technologies, choosing instead to rely on more affordable options that are already in use. This financial caution impedes market growth, as manufacturers face slower sales and fewer opportunities to expand production in cost-sensitive settings. Moreover, the significant initial investment required can deter smaller clinics from enhancing their infrastructure.

Market Trends of the Global Bronchopulmonary Dysplasia Market

The Global Bronchopulmonary Dysplasia market is witnessing a transformative trend driven by the integration of telehealth technologies. By enabling remote monitoring of preterm infants, neonatologists can now make timely adjustments to treatment protocols from anywhere, fostering improved patient outcomes. This shift reduces the logistical burdens on families, facilitating easier access to specialized care. The incorporation of wearable respiratory sensors and cloud-based analytics not only enhances data-driven decision-making but also promotes personalized treatment plans. As healthcare providers increasingly adopt home-based management strategies, the market for diagnostic and therapeutic solutions is expanding, reshaping traditional care models and broadening global reach.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Bronchopulmonary Dysplasia Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Pharmacological Treatment
• Respiratory Support
• Nutritional Therapy
• Others

Global Bronchopulmonary Dysplasia Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Corticosteroids
• Bronchodilators
• Diuretics
• Others

Global Bronchopulmonary Dysplasia Market Size by End User & CAGR (2026-2033)

• Market Overview
• Neonatal Intensive Care Units
• Hospitals
• Specialty Clinics
• Others

Global Bronchopulmonary Dysplasia Market Size by Patient Group & CAGR (2026-2033)

• Market Overview
• Preterm Infants
• Full-Term Infants

Global Bronchopulmonary Dysplasia Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Others

Global Bronchopulmonary Dysplasia Market Size by Disease Severity & CAGR (2026-2033)

• Market Overview
• Mild
• Moderate
• Severe

Global Bronchopulmonary Dysplasia Market Size & CAGR (2026-2033)

• North America (Treatment Type, Drug Class, End User, Patient Group, Distribution Channel, Disease Severity)
  • US
  • Canada
• Europe (Treatment Type, Drug Class, End User, Patient Group, Distribution Channel, Disease Severity)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Drug Class, End User, Patient Group, Distribution Channel, Disease Severity)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Drug Class, End User, Patient Group, Distribution Channel, Disease Severity)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Drug Class, End User, Patient Group, Distribution Channel, Disease Severity)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Chiesi Farmaceutici S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Airway Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orchard Therapeutics plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pneuma Respiratory, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Windtree Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Veru Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mereo BioPharma Group plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Savara Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aprea Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations